A Phase 1, Open-label, Randomized, Parallel-group, Single Dose Study to Assess the Relative Bioavailability of a New BMS-986419 Immediate-release Tablet Formulation Compared to a Reference Enteric Capsule (Delayed-release) Formulation, and to Assess the Effect of Food on the Pharmacokinetics of Immediate-release Tablet Formulation in Healthy Adult Participants
Latest Information Update: 31 Jan 2024
At a glance
- Drugs BMS-986419 (Primary) ; BMS-986419 (Primary)
- Indications Neurodegenerative disorders
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 22 Jan 2024 Status changed from recruiting to completed.
- 28 Aug 2023 Status changed from not yet recruiting to recruiting.
- 01 Aug 2023 New trial record